InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.000 -0.51 (-20.32%)+
Announcement
Release
4 Jun 2026 8:50AM
Price at Release
$2.510
Full Release
download
Summary
Racura Oncology Ltd has secured funding from a specialist institutional investor through a private placement of 526,315 shares at $1.90 each, raising a total of $31.2 million. This funding will support the development of RC220, their lead asset targeting cancer growth regulator MYC, which is currently in various clinical phases for several oncology applications. The placement, which did not involve broker fees, was designed to minimize dilution for existing shareholders. Racura Oncology is collaborating with numerous research institutions to further its clinical programs.
Key Points
  • Racura Oncology secures support from a specialist institutional investor through a private placement.
  • The placement involves 526,315 shares at $1.90 per share, a 23% discount to the average market price as of June 3.
  • The placement complements funds from Piggyback and Bonus Options, raising a total of $31.2 million.
  • Funds will support the clinical development of RC220 and general working capital.
  • Racura's lead asset, (E,E)-bisantrene, targets the MYC cancer growth regulator.
  • Racura is advancing RC220 in Phase 3 trials for acute myeloid leukaemia and other oncology indications.
  • Racura collaborates with several academic and research institutions.
  • No broker fees were involved in the placement, minimizing dilution to existing shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.